Blood purification therapy for severe sepsis: a multicenter, observational cohort study in northern Japan

Table 2 Differences in clinical outcomes between those treated with BPT and without BPT

	Mortality at discharge		Mortality at 28 days		28-day ICU-free days		ICU days		Hospital days
	N	p-value	N	p-value	Median	p-value	Median	p-value	Median	p-value
All (N = 616)	139/616 (22.6)	–	110/499 (22.0)	–	20.5 (5.0–25.0)	–	6.0 (3.0–11.5)	–	22.0 (12.0–51.0)	–
No BPT (N = 489)	90/487 (18.5)	REF	69/378 (22.0)	REF	22.0 (11.0–22.0)	REF	5.0 (3.0–11.0)	REF	21.0 (12.0–46.0)	REF
Any BPT (N = 127)	49/127 (38.6)	< 0.001	41/119 (34.5)	< 0.001	12.0 (0.0–21.0)	< 0.001	8.0 (4.0–16.0)	< 0.001	28.0 (13.0–69.0)	0.037
Any CRRT (N = 107)	44/107 (41.1)	< 0.001	37/99 (37.4)	< 0.001	9.0 (0.0–20.0)	< 0.001	8.0 (4.0–17.0)	< 0.001	27.0 (12.0–69.0)	0.090
CRRT for renal indications (N = 82)	40/82 (48.8)	< 0.001	33/78 (42.3)	< 0.001	3.0 (0.0–19.0)	0.003	8.0 (4.0–18.0)	0.001	26.5 (9.0–72.0)	0.416
CRRT for non-renal indications (N = 33)	7/33 (21.2)	0.833	6/29 (20.7)	0.744	17.0 (1.0–21.0)	< 0.001	9.0 (6.0–15.0)	0.003	34.0 (22.0–69.0)	0.011
IRRT (N = 28)	9/28 (32.1)	0.074	5/27 (18.5)	0.973	19.0 (7.5–23.0)	0.061	8.0 (4.5–14.0)	0.031	45.5 (26.0–70.5)	0.004
PMX-DHP (N = 42)	18/42 (42.9)	< 0.001	16/40 (40.0)	0.001	10.0 (0.0–21.0)	< 0.001	7.5 (3.0–17.0)	0.117	33.0 (14.0–64.0)	0.089

Data are expressed as medians (interquartile ranges) for continuous variables and numbers (%) for categorical variables
Missing data were not included. The Wilcoxon rank sum test was used for the continuous variables, and the Chi-square test was used for categorical variables
BPT blood purification therapy, CRRT continuous renal replacement therapy, IRRT intermittent renal replacement therapy, PMX-DHP polymyxin B immobilized fiber column-direct hemoperfusion, ICU intensive care unit, REF reference

ISSN: 2059-1381